Interestingly, CENPE inhibition with GSK923295 was recently described to synergize with PD-L1-targeted immunotherapy in NSCLC tumour models, which was attributed to CENPE inhibitor-mediated upregulation of PD-L1 [117]. Here, CENPE is linked to non-small cell lung carcinoma.